Epigenomics taps up Taapken
This article was originally published in Clinica
Executive Summary
Epigenomics, the German-American cancer molecular diagnostics company, has appointed Dr Thomas Taapken to serve as acting CEO in addition to his responsibilities as chief financial officer, effective 1 October 2012. Dr Taapken replaces Geert Nygaard who agreed with Epigenomics' supervisory board that he will leave the company effective 30 September, 2012.